Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | GNAS complex locus | Starlite/ChEMBL | No references |
Homo sapiens | TAR DNA binding protein | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Schistosoma mansoni | GTP-binding protein alpha subunit gna | GNAS complex locus | 394 aa | 450 aa | 28.7 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Onchocerca volvulus | 0.0012 | 0 | 0.5 | |
Onchocerca volvulus | 0.0012 | 0 | 0.5 | |
Loa Loa (eye worm) | GTP-binding regulatory protein Gs alpha-S chain | 0.0055 | 0.6688 | 0.6688 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 0.6688 | 0.6688 |
Onchocerca volvulus | 0.0012 | 0 | 0.5 | |
Loa Loa (eye worm) | TAR-binding protein | 0.0076 | 1 | 1 |
Onchocerca volvulus | 0.0012 | 0 | 0.5 | |
Loa Loa (eye worm) | variant SH3 domain-containing protein | 0.0019 | 0.1046 | 0.1046 |
Onchocerca volvulus | 0.0012 | 0 | 0.5 | |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 1 | 1 |
Entamoeba histolytica | protein kinase, putative | 0.0012 | 0 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 1 | 1 |
Brugia malayi | GTP-binding regulatory protein Gs alpha-S chain, putative | 0.0055 | 0.6688 | 0.6688 |
Brugia malayi | Variant SH3 domain containing protein | 0.0019 | 0.1046 | 0.1046 |
Entamoeba histolytica | SH2 domain containing protein | 0.0012 | 0 | 0.5 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 0.6688 | 0.6688 |
Onchocerca volvulus | 0.0012 | 0 | 0.5 | |
Schistosoma mansoni | vav2 | 0.0019 | 0.1046 | 0.1046 |
Onchocerca volvulus | Suppressor of cytokine signaling 7 homolog | 0.0012 | 0 | 0.5 |
Entamoeba histolytica | SH2-protein kinase domain containing protein | 0.0012 | 0 | 0.5 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 0.6688 | 0.6688 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 1 | 1 |
Onchocerca volvulus | 0.0012 | 0 | 0.5 | |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 1 | 1 |
Entamoeba histolytica | SH2-protein kinase domain containing protein | 0.0012 | 0 | 0.5 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0055 | 0.6688 | 0.6688 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0055 | 0.6688 | 0.6688 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0055 | 0.6688 | 0.6688 |
Onchocerca volvulus | 0.0012 | 0 | 0.5 | |
Brugia malayi | TAR-binding protein | 0.0076 | 1 | 1 |
Onchocerca volvulus | 0.0012 | 0 | 0.5 | |
Onchocerca volvulus | 0.0012 | 0 | 0.5 | |
Onchocerca volvulus | 0.0012 | 0 | 0.5 | |
Echinococcus multilocularis | tar DNA binding protein | 0.0076 | 1 | 1 |
Onchocerca volvulus | Suppressor of cytokine signaling at 36E homolog | 0.0012 | 0 | 0.5 |
Onchocerca volvulus | 0.0012 | 0 | 0.5 | |
Loa Loa (eye worm) | hypothetical protein | 0.0019 | 0.1046 | 0.1046 |
Loa Loa (eye worm) | RNA binding protein | 0.0076 | 1 | 1 |
Echinococcus granulosus | tar DNA binding protein | 0.0076 | 1 | 1 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0055 | 0.6688 | 0.6688 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0076 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 1 | 1 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0076 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.7943 uM | PubChem BioAssay. qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 8.2753 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 12.5893 uM | PubChem BioAssay. qHTS of TDP-43 Inhibitors. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 35.4813 um | PUBCHEM_BIOASSAY: qHTS Inhibitors of AmpC Beta-Lactamase (assay with detergent). (Class of assay: confirmatory) [Related pubchem assays: 1002 (Confirmation Concentration-Response Assay for Inhibitors of AmpC Beta-Lactamase (assay with detergent)), 585 (Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent) - a screen old NIH MLSMR collection), 584 (Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent) - a screen of the old NIH MLSMR collection), 1003 (Confirmation Cuvette-Based Assay for Inhibitors of AmpC Beta-Lactamase (assay with detergent))] | ChEMBL. | No reference |
Potency (functional) | = 39.8107 um | PUBCHEM_BIOASSAY: qHTS Assay for the Inhibitors of L3MBTL1. (Class of assay: confirmatory) [Related pubchem assays: 485292 (Probe Development Summary for Inhibitors of L3MBTL1)] | ChEMBL. | No reference |
Potency (functional) | 100 uM | PUBCHEM_BIOASSAY: HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.